Etzer Darout
Stock Analyst at BMO Capital
(3.00)
# 1,513
Out of 4,761 analysts
104
Total ratings
32.89%
Success rate
4.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $2.57 | +16.73% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.38 | +44.93% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $36.85 | +8.55% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $12.21 | +309.50% | 1 | Dec 6, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $62 | $38.75 | +60.00% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $16.87 | +107.47% | 1 | Dec 6, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Market Perform | $55 | $36.81 | +49.42% | 1 | Dec 6, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $63 | $5.96 | +957.05% | 1 | Dec 6, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $90 → $88 | $17.77 | +395.22% | 2 | Nov 20, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $28 → $27 | $5.54 | +387.36% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $79.49 | +68.57% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $15.74 | +116.01% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $22.34 | +114.86% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $109.35 | +9.74% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $37.70 | +0.80% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $4.01 | +549.19% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $5.72 | +337.06% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $2.76 | +81.16% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $3.01 | +564.45% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $47.37 | +92.10% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.42 | +322.54% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.78 | +360.26% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $123 → $122 | $120.01 | +1.66% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $74.22 | +10.48% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.84 | +322.54% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.23 | +263.29% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $250.59 | -32.16% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $7.28 | +1,053.85% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $51.84 | +4.17% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $52.45 | -27.55% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.24 | +2,221.43% | 1 | Mar 28, 2018 |
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.57
Upside: +16.73%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.38
Upside: +44.93%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $36.85
Upside: +8.55%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $12.21
Upside: +309.50%
Protagonist Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $62
Current: $38.75
Upside: +60.00%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $16.87
Upside: +107.47%
Kymera Therapeutics
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $36.81
Upside: +49.42%
Jasper Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.96
Upside: +957.05%
Arvinas
Nov 20, 2024
Maintains: Outperform
Price Target: $90 → $88
Current: $17.77
Upside: +395.22%
Acrivon Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $5.54
Upside: +387.36%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $79.49
Upside: +68.57%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $15.74
Upside: +116.01%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $22.34
Upside: +114.86%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $109.35
Upside: +9.74%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $37.70
Upside: +0.80%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $4.01
Upside: +549.19%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $5.72
Upside: +337.06%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $2.76
Upside: +81.16%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.01
Upside: +564.45%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $47.37
Upside: +92.10%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.42
Upside: +322.54%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.78
Upside: +360.26%
May 7, 2024
Maintains: Outperform
Price Target: $123 → $122
Current: $120.01
Upside: +1.66%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $74.22
Upside: +10.48%
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.84
Upside: +322.54%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.23
Upside: +263.29%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $250.59
Upside: -32.16%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $7.28
Upside: +1,053.85%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $51.84
Upside: +4.17%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $52.45
Upside: -27.55%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.24
Upside: +2,221.43%